WO2000034317A3 - Method for reducing immunogenicity of proteins - Google Patents
Method for reducing immunogenicity of proteins Download PDFInfo
- Publication number
- WO2000034317A3 WO2000034317A3 PCT/GB1999/004119 GB9904119W WO0034317A3 WO 2000034317 A3 WO2000034317 A3 WO 2000034317A3 GB 9904119 W GB9904119 W GB 9904119W WO 0034317 A3 WO0034317 A3 WO 0034317A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- epitopes
- proteins
- humans
- self
- reducing immunogenicity
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
- C12N9/6418—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals from snakes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000586759A JP2002534959A (en) | 1998-12-08 | 1999-12-08 | Methods for modifying immunogenic proteins |
AU16676/00A AU776910B2 (en) | 1998-12-08 | 1999-12-08 | Modifying protein immunogenicity |
DE69934967T DE69934967T2 (en) | 1998-12-08 | 1999-12-08 | METHOD FOR REDUCING IMMUNOGENICITY OF PROTEINS |
CA002342967A CA2342967A1 (en) | 1998-12-08 | 1999-12-08 | Modifying protein immunogenicity |
EP99959535A EP1051432B1 (en) | 1998-12-08 | 1999-12-08 | Method for reducing immunogenicity of proteins |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9826925.1A GB9826925D0 (en) | 1998-12-08 | 1998-12-08 | Therapeutic non-homologous proteins |
GBGB9902139.6A GB9902139D0 (en) | 1999-02-02 | 1999-02-02 | Therapeutic non-autologous proteins |
GB9826925.1 | 1999-02-02 | ||
GB9902139.6 | 1999-02-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000034317A2 WO2000034317A2 (en) | 2000-06-15 |
WO2000034317A3 true WO2000034317A3 (en) | 2000-08-17 |
Family
ID=26314799
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1999/004119 WO2000034317A2 (en) | 1998-12-08 | 1999-12-08 | Method for reducing immunogenicity of proteins |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1051432B1 (en) |
JP (1) | JP2002534959A (en) |
CN (1) | CN1202128C (en) |
AT (1) | ATE352559T1 (en) |
AU (1) | AU776910B2 (en) |
CA (1) | CA2342967A1 (en) |
DE (1) | DE69934967T2 (en) |
ES (1) | ES2278463T3 (en) |
WO (1) | WO2000034317A2 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8524470B2 (en) | 2009-07-30 | 2013-09-03 | Hoffman-La Roche, Inc. | Enzymatic antibody processing |
US8691952B2 (en) | 2005-12-30 | 2014-04-08 | Merck Patent Gmbh | Anti-CD19 antibodies with reduced immunogenicity |
US8835606B2 (en) | 2004-01-22 | 2014-09-16 | Merck Patent Gmbh | Anti-cancer antibodies with reduced complement fixation |
US9011852B2 (en) | 2010-04-30 | 2015-04-21 | Alexion Pharmaceuticals, Inc. | Anti-C5a antibodies |
US9066925B2 (en) | 2009-07-02 | 2015-06-30 | Musc Foundation For Research Development | Methods of stimulating liver regeneration |
US9096651B2 (en) | 2007-09-26 | 2015-08-04 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in CDR |
US9133273B2 (en) | 2010-11-19 | 2015-09-15 | Eisai R&D Management Co., Ltd. | Nucleic acids encoding neutralizing anti-CCL20 antibodies |
US9221915B2 (en) | 2005-09-07 | 2015-12-29 | Pfizer Inc. | Human monoclonal antibodies to activin receptor-like kinase-1 |
US9228017B2 (en) | 2009-03-19 | 2016-01-05 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
US9399680B2 (en) | 2007-12-05 | 2016-07-26 | Chugai Seiyaku Kabushiki Kaisha | Nucleic acids encoding anti-NR10 antibodies |
Families Citing this family (345)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
US20020068303A1 (en) * | 1994-07-14 | 2002-06-06 | Ruth Laub | Antigenic polypeptide sequences of factor VIII, and fragments and/or epitopes of these sequences |
US6936249B1 (en) | 1998-04-15 | 2005-08-30 | Genencor International, Inc. | Proteins producing an altered immunogenic response and methods of making and using the same |
US6838269B1 (en) | 1998-04-15 | 2005-01-04 | Genencor International, Inc. | Proteins producing an altered immunogenic response and methods of making and using the same |
US7833528B2 (en) | 1998-06-22 | 2010-11-16 | Immunomedics, Inc. | Use of multispecific, non-covalent complexes for targeted delivery of therapeutics |
US7405320B2 (en) | 1998-06-22 | 2008-07-29 | Immunomedics, Inc. | Therapeutic and diagnostic conjugates for use with multispecific antibodies |
US6962702B2 (en) | 1998-06-22 | 2005-11-08 | Immunomedics Inc. | Production and use of novel peptide-based agents for use with bi-specific antibodies |
US7387772B1 (en) | 1999-06-22 | 2008-06-17 | Immunimedics, Inc. | Chimeric, human and humanized anti-CSAP monoclonal antibodies |
US7138103B2 (en) | 1998-06-22 | 2006-11-21 | Immunomedics, Inc. | Use of bi-specific antibodies for pre-targeting diagnosis and therapy |
EA004590B1 (en) | 1999-01-15 | 2004-06-24 | Байоджен, Инк. | Method for blocking the development or treating or reducing the severity or effects of "transplant against patients" disease |
US7947496B2 (en) | 1999-10-08 | 2011-05-24 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
WO2001040281A2 (en) * | 1999-12-02 | 2001-06-07 | Thromb-X N.V. | Method for reducing the immunogenicity of heterologous proteins by elimination of t-cell epitopes |
AU2001278898A1 (en) * | 2000-07-10 | 2002-01-21 | Xencor | Method for disigning protein libraries with altered immunogenicity |
GB0018901D0 (en) * | 2000-08-03 | 2000-09-20 | Biovation Ltd | Peptides presented by cells |
ATE504205T1 (en) * | 2000-10-02 | 2011-04-15 | Danisco Us Inc | METHOD FOR DETERMINING THE IMMUNOGENICITY OF PROTEINS THAT PRODUCE AN ALTERED IMMUNE RESPONSE |
US6673580B2 (en) * | 2000-10-27 | 2004-01-06 | Genentech, Inc. | Identification and modification of immunodominant epitopes in polypeptides |
US7534429B2 (en) | 2000-11-29 | 2009-05-19 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD63 |
HUP0402071A2 (en) * | 2001-02-06 | 2005-01-28 | Merck Patent Gmbh. | Modified leptin with reduced immunogenicity |
PL362396A1 (en) * | 2001-02-06 | 2004-11-02 | Merck Patent Gmbh | Modified erythropoietin (epo) with reduced immunogenicity |
PL362412A1 (en) * | 2001-02-06 | 2004-11-02 | Merck Patent Gmbh | Modified interleukin-1 receptor antagonist (il-1ra) with reduced immunogenicity |
HUP0402041A2 (en) * | 2001-02-06 | 2005-01-28 | Merck Patent Gmbh | Modified granulocyte colony stimulating (g-csf) with reduced immunogenicity |
BR0207017A (en) * | 2001-02-06 | 2004-02-03 | Merck Patent Gmbh | Modified keratinocyte growth factor (kgf) with reduced immunogenicity |
BR0207016A (en) * | 2001-02-06 | 2004-02-03 | Merck Patent Gmbh | Modified human brain derived neurotrophic factor (bdnf) with reduced immunogenicity |
ZA200305980B (en) * | 2001-02-12 | 2007-01-31 | Res Dev Foundation | Modified proteins, designer toxins, and methods of making thereof |
EP1361893B1 (en) * | 2001-02-19 | 2012-10-24 | Merck Patent GmbH | Modified anti-egfr antibodies with reduced immunogenicity |
CN100404673C (en) | 2001-02-19 | 2008-07-23 | 默克专利有限公司 | Method for identification of T-cell epitopes and use for preparing molecules with reduced immunogenicity |
BR0207267A (en) * | 2001-02-19 | 2004-02-10 | Merck Patent Gmbh | Artificial proteins with reduced immunogenicity |
KR20030082962A (en) * | 2001-03-08 | 2003-10-23 | 메르크 파텐트 게엠베하 | Modified granulocyte macrophage colony stimulating factor (gm-csf) with reduced immunogenicity |
MXPA03008310A (en) * | 2001-03-15 | 2003-12-11 | Merck Patent Gmbh | Modified interferon beta with reduced immunogenicity. |
JP2004533817A (en) * | 2001-03-20 | 2004-11-11 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | Modified insulin with reduced immunogenicity |
US6992174B2 (en) * | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
JP4619651B2 (en) | 2001-06-01 | 2011-01-26 | コーネル・リサーチ・ファンデーション・インコーポレイテッド | Modified antibodies against prostate-specific membrane antigen and uses thereof |
US7666414B2 (en) | 2001-06-01 | 2010-02-23 | Cornell Research Foundation, Inc. | Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen |
WO2003000736A1 (en) | 2001-06-26 | 2003-01-03 | Agen Biomedical Limited | Humanized antibodies derived from dd-3b6/22, specific for the d-dimer fragment of fibrin |
JP2004535202A (en) | 2001-07-17 | 2004-11-25 | リサーチ ディベロップメント ファンデーション | Therapeutic agents containing pro-apoptotic proteins |
MXPA04001982A (en) * | 2001-09-04 | 2004-06-07 | Merck Patent Gmbh | Modified factor ix. |
HUP0402334A3 (en) * | 2001-09-04 | 2007-03-28 | Merck Patent Gmbh | Modified human growth hormone |
AR039067A1 (en) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | ANTIBODIES FOR CD40 |
MXPA04004417A (en) * | 2001-11-12 | 2004-08-11 | Merck Patent Gmbh | Modified anti-tnf alpha antibody. |
US20030100016A1 (en) * | 2001-11-23 | 2003-05-29 | George Jackowski | Complement C3 precursor biopolymer markers predictive of Alzheimers disease |
NZ548701A (en) | 2002-04-09 | 2008-03-28 | Biogen Idec Inc | Methods for treating tweak-related conditions |
JP2005538694A (en) * | 2002-04-18 | 2005-12-22 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | Modified factor VIII |
DK1531791T3 (en) | 2002-06-07 | 2010-11-01 | Dyax Corp | Prevention and restriction of ischemia |
US7153829B2 (en) | 2002-06-07 | 2006-12-26 | Dyax Corp. | Kallikrein-inhibitor therapies |
JP2005535304A (en) * | 2002-06-11 | 2005-11-24 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | Modified bryodin1 with reduced immunogenicity |
PT1512004E (en) * | 2002-06-11 | 2006-08-31 | Merck Patent Gmbh | METHOD FOR MAPPING AND ELIMINATING EPITHOPES FOR T-CELLS |
DE10233047A1 (en) * | 2002-07-19 | 2004-02-26 | Amaxa Gmbh | Preparing synthetic polypeptides, particularly fluorescent proteins, useful in pharmaceutical compositions, by aligning sequences of known proteins to define an average sequence |
US20040018568A1 (en) * | 2002-07-23 | 2004-01-29 | Subhashis Banerjee | Methods for detecting deantigenized T cell epitopes and uses thereof |
WO2004014938A2 (en) * | 2002-08-09 | 2004-02-19 | Xencor | Thrombopoiesis-stimulating proteins having reduced immunogenicity |
EP1527094B1 (en) * | 2002-08-09 | 2008-07-16 | MERCK PATENT GmbH | T-cell epitopes in erythropoietin |
ES2395014T3 (en) | 2002-08-28 | 2013-02-07 | Dyax Corp. | Methods to preserve organs and tissues |
DK1569685T3 (en) * | 2002-11-15 | 2012-11-12 | Univ Colorado Regents | Complement modulators targeting complement receptor-2 |
CA2510180C (en) | 2002-12-17 | 2012-09-11 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2 |
US7488475B2 (en) | 2003-01-21 | 2009-02-10 | Arius Research, Inc. | Antibody therapy of tumors |
RS54160B1 (en) | 2003-03-19 | 2015-12-31 | Biogen Idec Ma Inc. | Nogo receptor binding protein |
US20070224196A1 (en) * | 2003-03-28 | 2007-09-27 | Elusys Therapeutics, Inc. | Immunogenicity-reduced anti-cr1 antibody and compositions and methods of treatment based thereon |
EP1641827A2 (en) | 2003-06-27 | 2006-04-05 | Biogen Idec MA Inc. | Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions |
AR045563A1 (en) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | ANTIBODIES DIRECTED TO M-CSF |
DK1673398T3 (en) | 2003-10-16 | 2011-04-18 | Micromet Ag | Multispecific, deimmunized CD3 binders |
ATE552276T1 (en) | 2003-11-01 | 2012-04-15 | Merck Patent Gmbh | MODIFIED ANTI-CD52 ANTIBODY |
WO2005044304A2 (en) | 2003-11-04 | 2005-05-19 | Chiron Corporation | Use of antagonist anti-cd40 antibodies for treatment of chronic lymphocytic leukemia |
EP2301575A1 (en) | 2003-11-04 | 2011-03-30 | Novartis Vaccines and Diagnostics, Inc. | Methods of therapy for solid tumors expressing the CD40 cell-surface antigen |
EP2236172A1 (en) | 2003-11-04 | 2010-10-06 | Novartis Vaccines and Diagnostics, Inc. | Combination therapy comprising anti-CD20 and anti-CD40 antibodies for the treatment of B cell-related cancers |
ES2346978T3 (en) | 2003-11-04 | 2010-10-22 | Novartis Vaccines And Diagnostics, Inc. | USE OF ANTI-CD40 ANTIGONIST MONOCLONANT ANTIBODIES FOR THE TREATMENT OF MULTIPLE MYELOMA. |
EP1694360B1 (en) | 2003-11-04 | 2010-08-04 | Novartis Vaccines and Diagnostics, Inc. | Use of antagonist anti-cd40 antibodies for treatment of autoimmune and inflammatory diseases and organ transplant rejection |
EP1697415A1 (en) | 2003-11-12 | 2006-09-06 | Biogen Idec MA Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
EP1697741A4 (en) | 2003-12-04 | 2008-02-13 | Xencor Inc | Methods of generating variant proteins with increased host string content and compositions thereof |
US20060122783A1 (en) * | 2004-08-24 | 2006-06-08 | Ishikawa Muriel Y | System and method for heightening a humoral immune response |
EA010803B1 (en) | 2004-03-19 | 2008-12-30 | Мерк Патент Гмбх | Modified bouganin proteins, cytotoxins and methods and uses thereof |
CN1954073B (en) * | 2004-03-19 | 2013-01-16 | 默克专利股份有限公司 | Modified Bouganin proteins, cytotoxins and methods and uses thereof |
CA2572193A1 (en) | 2004-06-24 | 2006-01-05 | Biogen Idec Ma Inc. | Treatment of conditions involving oligodendrocytes with sp35 based agents |
US7846438B2 (en) | 2004-08-03 | 2010-12-07 | Biogen Idec Ma Inc. | Methods of promoting neurite outgrowth with soluble TAJ polypeptides |
US20060073563A1 (en) * | 2004-09-02 | 2006-04-06 | Xencor, Inc. | Erythropoietin derivatives with altered immunogenicity |
US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
DK1817340T3 (en) | 2004-11-12 | 2012-08-13 | Xencor Inc | FC VARIATIONS WITH CHANGED BINDING TO FCRN |
AU2006210724A1 (en) * | 2005-02-03 | 2006-08-10 | Antitope Limited | Human antibodies and proteins |
EP1859277A4 (en) | 2005-02-17 | 2010-03-17 | Biogen Idec Inc | Treating neurological disorders |
JP5153613B2 (en) * | 2005-03-18 | 2013-02-27 | メディミューン,エルエルシー | Antibody framework shuffle |
CA2601400A1 (en) | 2005-03-19 | 2006-09-28 | Medical Research Council | Improvements in or relating to treatment and prevention of viral infections |
EP1868647A4 (en) | 2005-03-24 | 2009-04-01 | Millennium Pharm Inc | Antibodies that bind ov064 and methods of use therefor |
TW200720289A (en) | 2005-04-01 | 2007-06-01 | Hoffmann La Roche | Antibodies against CCR5 and uses thereof |
MX2007013217A (en) | 2005-04-25 | 2008-03-11 | Pfizer | Antibodies to myostatin. |
AP2552A (en) | 2005-04-26 | 2013-01-08 | Pfizer | P-cadherin antibodies |
JP5339901B2 (en) | 2005-05-10 | 2013-11-13 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Treatment and evaluation of inflammatory injury |
JP5421590B2 (en) | 2005-05-18 | 2014-02-19 | ノバルティス アーゲー | Methods for diagnosis and treatment of diseases with autoimmune and / or inflammatory components |
EA018255B1 (en) | 2005-05-27 | 2013-06-28 | Байоджен Айдек Ма Инк. | Tweak binding proteins and use thereof |
WO2006138219A2 (en) | 2005-06-13 | 2006-12-28 | Biogen Idec Ma Inc. | Methods of diagnosis / prognosis of inflammatory conditions |
EP1904531B1 (en) * | 2005-07-08 | 2010-10-06 | Pfizer Limited | Madcam antibodies |
EP2238986A3 (en) | 2005-07-08 | 2010-11-03 | Biogen Idec MA Inc. | Sp35 antibodies and uses thereof |
US20070184487A1 (en) * | 2005-07-12 | 2007-08-09 | Baynes Brian M | Compositions and methods for design of non-immunogenic proteins |
US7456259B2 (en) | 2005-08-02 | 2008-11-25 | Arius Research, Inc. | Cancerous disease modifying antibodies |
US7452979B2 (en) | 2005-08-02 | 2008-11-18 | Arius Research, Inc. | Cancerous disease modifying antibodies |
US7452978B2 (en) | 2005-08-02 | 2008-11-18 | Arius Research, Inc. | Cancerous disease modifying antibodies |
US7456258B2 (en) | 2005-08-02 | 2008-11-25 | Arius Research, Inc. | Cancerous disease modifying antibodies |
US7494648B2 (en) | 2005-08-02 | 2009-02-24 | Hoffmann-La Roche Inc. | Cancerous disease modifying antibodies |
US7411046B2 (en) | 2005-08-02 | 2008-08-12 | Arius Research Inc | Cancerous disease modifying antibodies |
EP1919951B1 (en) * | 2005-08-04 | 2015-01-28 | Janssen Biotech, Inc. | Anti-tnf-alpha antibodies and methods of use |
CA2625440C (en) | 2005-10-11 | 2023-06-13 | Micromet Ag | Compositions comprising cross-species-specific antibodies and uses thereof |
NZ568705A (en) | 2005-11-04 | 2012-07-27 | Biogen Idec Inc | Methods for promoting neurite outgrowth and survival of dopaminergic neurons |
NZ598421A (en) | 2005-12-02 | 2013-11-29 | Biogen Idec Inc | Treatment of Conditions Involving Demyelination |
DK1976880T3 (en) | 2005-12-21 | 2016-09-26 | Amgen Res (Munich) Gmbh | Pharmaceutical compositions with resistance to soluble cea |
ATE555125T1 (en) | 2005-12-30 | 2012-05-15 | Merck Patent Gmbh | INTERLEUKIN 12P40 VARIANTS WITH IMPROVED STABILITY |
WO2007084321A2 (en) | 2006-01-12 | 2007-07-26 | Alexion Pharmaceuticals, Inc. | Antibodies to ox-2/cd200 and uses thereof |
US8669345B2 (en) | 2006-01-27 | 2014-03-11 | Biogen Idec Ma Inc. | Nogo receptor antagonists |
TWI417301B (en) | 2006-02-21 | 2013-12-01 | Wyeth Corp | Antibodies against human il-22 and uses therefor |
TW200744634A (en) | 2006-02-21 | 2007-12-16 | Wyeth Corp | Methods of using antibodies against human IL-22 |
ES2568436T3 (en) | 2006-03-31 | 2016-04-29 | Chugai Seiyaku Kabushiki Kaisha | Procedure to control the blood pharmacokinetics of antibodies |
EA018301B1 (en) | 2006-04-21 | 2013-07-30 | Новартис Аг | Pharmaceutical compositions comprising antagonist monoclonal anti-cd40 antibody and use thereof |
ES2429407T3 (en) | 2006-06-08 | 2013-11-14 | Chugai Seiyaku Kabushiki Kaisha | Preventive agent or remedy for inflammatory diseases |
SI2044111T1 (en) | 2006-06-21 | 2015-02-27 | Musc Foundation For Research Development | Targeting complement factor h for treatment of diseases |
AU2007281774A1 (en) | 2006-08-04 | 2008-02-14 | Astrazeneca Ab | Human antibodies to ErbB 2 |
AU2007286451A1 (en) | 2006-08-17 | 2008-02-21 | F. Hoffmann-La Roche Ag | A conjugate of an antibody against CCR5 and an antifusogenic peptide |
TW200817438A (en) | 2006-08-17 | 2008-04-16 | Hoffmann La Roche | A conjugate of an antibody against CCR5 and an antifusogenic peptide |
US8093360B2 (en) | 2006-09-28 | 2012-01-10 | Elusys Therapeutics, Inc. | Antibodies that bind B. anthracis exotoxin, formulations thereof, and methods of use |
KR20090069330A (en) | 2006-10-12 | 2009-06-30 | 와이어쓰 | Modification of ionic strength in antibody-solutions to reduce opalescence/aggregates |
MX2009004519A (en) | 2006-11-03 | 2009-05-12 | Wyeth Corp | Glycolysis-inhibiting substances in cell culture. |
US8129502B2 (en) | 2006-11-13 | 2012-03-06 | Hoffmann-La Roche Inc. | Cancerous disease modifying antibodies |
BRPI0719109A2 (en) | 2006-11-21 | 2013-12-10 | Kalobios Pharmaceuticals Inc | METHODS TO TREAT CHRONIC INFLAMMATORY DISEASES USING A GM-CSF ANTAGONIST |
CN103408661B (en) | 2007-01-05 | 2016-04-06 | 苏黎世大学 | The method of disease-specific binding molecules and target is provided |
US8128926B2 (en) | 2007-01-09 | 2012-03-06 | Biogen Idec Ma Inc. | Sp35 antibodies and uses thereof |
AU2008205244B2 (en) | 2007-01-09 | 2013-02-07 | Biogen Ma Inc. | Sp35 antibodies and uses thereof |
EP2136838B1 (en) | 2007-03-08 | 2017-03-08 | KaloBios Pharmaceuticals, Inc. | Epha3 antibodies for the treatment of solid tumors |
PE20081899A1 (en) | 2007-04-02 | 2009-01-26 | Pfizer | ANTI-IGE ANTIBODIES |
JP2010530895A (en) * | 2007-06-21 | 2010-09-16 | アンジェリカ セラピューティックス,インク. | Modified toxin |
BRPI0815567B8 (en) | 2007-07-17 | 2021-05-25 | Merck Patent Gessellschaft Mit Beschraenkter Haftung | engineered anti-alpha v-integrin hybrid antibodies, fusion protein and pharmaceutical composition |
CL2008002092A1 (en) | 2007-07-20 | 2009-05-29 | Hoffmann La Roche | Conjugate containing two or more antifusogenic peptides and an anti-cd-4 antibody; Method of production; pharmaceutical composition comprising it; antifusogenic polypeptides and use of the conjugate to treat viral infections. |
BRPI0815399A2 (en) * | 2007-08-13 | 2019-09-24 | Vasgene Therapeutics Inc | cancer treatment using humanized antibodies that bind ephb4 |
SG10201605394SA (en) | 2007-09-26 | 2016-08-30 | Chugai Pharmaceutical Co Ltd | Modified Antibody Constant Region |
JP5951929B2 (en) | 2007-10-03 | 2016-07-13 | コーネル ユニヴァーシティー | Treatment of proliferative disorders using PSMA antibodies |
AU2008309934B2 (en) | 2007-10-12 | 2014-03-06 | F. Hoffmann-La Roche Ag | Protein expression from multiple nucleic acids |
WO2015164330A1 (en) | 2014-04-21 | 2015-10-29 | Millennium Pharmaceuticals, Inc. | Anti-psyk antibody molecules and use of same for syk-targeted therapy |
MX2010006097A (en) | 2007-12-05 | 2010-08-04 | Chugai Pharmaceutical Co Ltd | Therapeutic agent for pruritus. |
CN103399145B (en) | 2007-12-15 | 2015-06-24 | 霍夫曼-拉罗奇有限公司 | Distinguishing assay |
ES2532461T3 (en) | 2007-12-26 | 2015-03-27 | Xencor, Inc. | FC variants with altered FCRN binding |
JP2011510015A (en) | 2008-01-15 | 2011-03-31 | カロバイオス ファーマシューティカルズ インコーポレイティッド | Method for treating bone loss disorder using GM-CSF antagonist |
WO2009102421A2 (en) | 2008-02-14 | 2009-08-20 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins that bind egfr |
WO2009110944A1 (en) * | 2008-02-29 | 2009-09-11 | Angelica Therapeutics, Inc. | Modified toxins |
EP4238993A3 (en) | 2008-04-11 | 2023-11-29 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
TWI547287B (en) | 2008-04-25 | 2016-09-01 | 戴埃克斯有限公司 | Fc receptor binding proteins |
JP2011520961A (en) | 2008-05-22 | 2011-07-21 | ブリストル−マイヤーズ スクイブ カンパニー | Scaffold domain protein based on multivalent fibronectin |
AU2009269099B2 (en) | 2008-07-09 | 2016-03-10 | Biogen Ma Inc. | Compositions comprising antibodies to LINGO or fragments thereof |
JP2012504939A (en) | 2008-09-23 | 2012-03-01 | ワイス・エルエルシー | Method for predicting the generation of activation signals by cross-linked proteins |
JP2012505900A (en) | 2008-10-14 | 2012-03-08 | ダイアクス コーポレーション | Use of an IGF-II / IGF-IIE binding protein for the treatment and prevention of pulmonary fibrosis associated with systemic scleroderma |
WO2010056550A1 (en) | 2008-10-29 | 2010-05-20 | Wyeth Llc | Methods for purification of single domain antigen binding molecules |
CN102271707B (en) | 2008-10-29 | 2015-04-08 | 阿布林克斯公司 | Formulations of single domain antigen binding molecules |
AU2009313203B2 (en) | 2008-11-10 | 2015-08-27 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating complement-associated disorders |
TWI496582B (en) | 2008-11-24 | 2015-08-21 | 必治妥美雅史谷比公司 | Bispecific egfr/igfir binding molecules |
PL2949666T3 (en) | 2008-12-19 | 2019-07-31 | Biogen International Neuroscience Gmbh | Human anti-alpha-synuclein antibodies |
CN102341411A (en) | 2008-12-31 | 2012-02-01 | 比奥根艾迪克Ma公司 | Anti-lymphotoxin antibodies |
WO2010080833A1 (en) | 2009-01-06 | 2010-07-15 | Dyax Corp. | Treatment of mucositis with kallikrein inhibitors |
CN102348715B (en) | 2009-02-03 | 2017-12-08 | 阿穆尼克斯运营公司 | Extension recombinant polypeptide and the composition for including the extension recombinant polypeptide |
WO2010093814A1 (en) | 2009-02-11 | 2010-08-19 | Kalobios Pharmaceuticals, Inc. | Methods of treating dementia using a gm-csf antagonist |
EP2398504B1 (en) | 2009-02-17 | 2018-11-28 | Cornell Research Foundation, Inc. | Methods and kits for diagnosis of cancer and prediction of therapeutic value |
CA2753995A1 (en) | 2009-03-06 | 2010-09-10 | Kalobios Pharmaceuticals, Inc. | Treatment of leukemias and chronic myeloproliferative diseases with antibodies to epha3 |
JP5787446B2 (en) | 2009-03-19 | 2015-09-30 | 中外製薬株式会社 | Antibody constant region variants |
EP2411412B1 (en) | 2009-03-24 | 2015-05-27 | Teva Biopharmaceuticals USA, Inc. | Humanized antibodies against light and uses thereof |
CA2759333A1 (en) | 2009-04-22 | 2010-10-28 | Merck Patent Gmbh | Antibody fusion proteins with modified fcrn binding sites |
AR076770A1 (en) | 2009-05-13 | 2011-07-06 | Genzyme Corp | ANTI-CD52 HUMAN IMMUNOGLOBULINS |
JP2012531212A (en) | 2009-07-03 | 2012-12-10 | アビペップ ピーティーワイ リミテッド | Immunoconjugate and method for producing the same |
WO2011004899A1 (en) | 2009-07-06 | 2011-01-13 | Takeda Pharmaceutical Company Limited | Cancerous disease modifying antibodies |
WO2011003996A1 (en) | 2009-07-09 | 2011-01-13 | F. Hoffmann-La Roche Ag | In vivo tumor vasculature imaging |
KR20120041247A (en) | 2009-09-07 | 2012-04-30 | 에프. 호프만-라 로슈 아게 | Es-ms of glycopeptides for analysis of glycosylation |
KR101834890B1 (en) | 2009-10-23 | 2018-04-20 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | Anti-gcc antibody molecules and related compositions and methods |
MX2012005164A (en) | 2009-11-05 | 2012-10-03 | Cephalon Australia Pty Ltd | Treatment of cancer involving mutated kras or braf genes. |
KR20120130748A (en) | 2009-11-05 | 2012-12-03 | 알렉시온 캠브리지 코포레이션 | Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis |
MX2012005388A (en) | 2009-11-09 | 2012-07-23 | Alexion Pharma Inc | Reagents and methods for detecting pnh type ii white blood cells and their identification as risk factors for thrombotic disorders. |
SG181814A1 (en) | 2009-12-23 | 2012-07-30 | Avipep Pty Ltd | Immuno-conjugates and methods for producing them 2 |
RS57870B1 (en) | 2010-01-06 | 2018-12-31 | Dyax Corp | Plasma kallikrein binding proteins |
EP2523976B1 (en) | 2010-01-11 | 2018-04-25 | Alexion Pharmaceuticals, Inc. | Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies |
TW201138808A (en) | 2010-05-03 | 2011-11-16 | Bristol Myers Squibb Co | Serum albumin binding molecules |
ES2717912T3 (en) | 2010-05-14 | 2019-06-26 | Univ Colorado Regents | Groups targeted to complement receptor 2 (cr2) improved |
KR20130036276A (en) | 2010-06-22 | 2013-04-11 | 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 | Antibodies to the c3d fragment of complement component 3 |
US20120100166A1 (en) | 2010-07-15 | 2012-04-26 | Zyngenia, Inc. | Ang-2 Binding Complexes and Uses Thereof |
CA2805572A1 (en) | 2010-07-16 | 2012-01-19 | Martin Hegen | Modified single domain antigen binding molecules and uses thereof |
MX341309B (en) | 2010-07-20 | 2016-08-12 | Cephalon Australia Pty Ltd | Anti-il-23 heterodimer specific antibodies. |
WO2012019061A2 (en) | 2010-08-05 | 2012-02-09 | Stem Centrx, Inc. | Novel effectors and methods of use |
EP2420250A1 (en) | 2010-08-13 | 2012-02-22 | Universitätsklinikum Münster | Anti-Syndecan-4 antibodies |
AU2011293127B2 (en) | 2010-08-27 | 2016-05-12 | Abbvie Stemcentrx Llc | Notum protein modulators and methods of use |
WO2012031273A2 (en) | 2010-09-03 | 2012-03-08 | Stem Centrx, Inc. | Novel modulators and methods of use |
CA2809632A1 (en) | 2010-10-05 | 2012-04-12 | Monika Baehner | Antibodies against human tweak and uses thereof |
SG190727A1 (en) | 2010-11-30 | 2013-07-31 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
WO2012075111A1 (en) | 2010-11-30 | 2012-06-07 | Novartis Ag | Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers |
EP2471543A1 (en) | 2010-12-02 | 2012-07-04 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Tolerance induction or immunosupression to prevent in particular Graft-versus-Host-Disease (GvHD) by short-term pre-incubation of transplanted cell suspensions, tissues or organs coated with ligands to cell surface molecules |
MX356400B (en) | 2010-12-08 | 2018-05-28 | Abbvie Stemcentrx Llc | Novel modulators and methods of use. |
CN103380145B (en) | 2010-12-17 | 2016-10-12 | 生物控股有限公司 | The mankind's anti-SOD1 antibody |
WO2012083370A1 (en) | 2010-12-22 | 2012-06-28 | Cephalon Australia Pty Ltd | Modified antibody with improved half-life |
KR102107695B1 (en) | 2011-01-06 | 2020-05-07 | 다이액스 코포레이션 | Plasma kallikrein binding proteins |
US9447187B2 (en) | 2011-02-03 | 2016-09-20 | Alexion Pharmaceuticals, Inc. | Use of an anti-CD200 antibody for prolonging the survival of allografts |
JP6320042B2 (en) | 2011-02-11 | 2018-05-09 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | Anti-alpha-V integrin antibody for prostate cancer treatment |
SA112330278B1 (en) | 2011-02-18 | 2015-10-09 | ستيم سينتركس، انك. | Novel modulators and methods of use |
WO2012119989A2 (en) | 2011-03-04 | 2012-09-13 | Oryzon Genomics, S.A. | Methods and antibodies for the diagnosis and treatment of cancer |
EP2686016B1 (en) | 2011-03-14 | 2019-05-01 | Cellmid Limited | Antibody recognizing n-domain of midkine |
JP6130350B2 (en) | 2011-03-30 | 2017-05-17 | アブリンクス エン.ヴェー. | Methods of treating immune disorders with single domain antibodies against TNFα |
JP6038121B2 (en) | 2011-04-21 | 2016-12-07 | ガーバン インスティテュート オブ メディカル リサーチ | Modified variable domain molecules and methods for their production and use B |
CN103857699B (en) | 2011-05-24 | 2016-08-31 | 泽恩格尼亚股份有限公司 | Multivalence and unit price polyspecific complex and application thereof |
BR112013030352B1 (en) | 2011-06-02 | 2020-05-19 | Dyax Corp | isolated anti-fcrn antibody, pharmaceutical composition comprising said antibody, isolated nucleic acid, vector, cell and therapeutic use of said antibody |
DK2718320T3 (en) | 2011-06-10 | 2018-03-26 | Medimmune Ltd | ANTI-PSEUDOMONAS-PSL BINDING MOLECULES AND APPLICATIONS THEREOF |
WO2012171057A1 (en) | 2011-06-13 | 2012-12-20 | Csl Limited | Antibodies against g-csfr and uses thereof |
SI2723379T1 (en) | 2011-06-23 | 2019-03-29 | Biogen International Neuroscience Gmbh | Anti-alpha synuclein binding molecules |
US9738707B2 (en) | 2011-07-15 | 2017-08-22 | Biogen Ma Inc. | Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto |
US20130058947A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc | Novel Modulators and Methods of Use |
US9447192B2 (en) | 2011-09-09 | 2016-09-20 | Medimmune Limited | Anti-Siglec-15 antibodies and uses thereof |
WO2013039954A1 (en) | 2011-09-14 | 2013-03-21 | Sanofi | Anti-gitr antibodies |
JP2014533929A (en) | 2011-09-23 | 2014-12-18 | アムゲン リサーチ (ミュンヘン) ゲーエムベーハー | Bispecific binding molecules for 5T4 and CD3 |
WO2013044298A1 (en) | 2011-09-30 | 2013-04-04 | Cephalon Australia Pty Ltd | Antibodies against tl1a and uses thereof |
SG2014012470A (en) | 2011-10-05 | 2014-06-27 | Hoffmann La Roche | Process for antibody g1 glycoform production |
JP2015504413A (en) | 2011-10-28 | 2015-02-12 | パトリス リミテッド | PAT-LM1 epitope and methods for using the same |
CN104271599A (en) | 2011-11-08 | 2015-01-07 | 辉瑞公司 | Methods of treating inflammatory disorders using anti-M-CSF antibodies |
TWI679212B (en) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | Binding molecules for e3 of bcma and cd3 |
EP2785364B1 (en) | 2011-11-29 | 2019-01-09 | Proclara Biosciences, Inc. | Use of p3 of bacteriophage as amyloid binding agents |
CA2857721C (en) | 2011-12-05 | 2022-05-31 | X-Body, Inc. | Pdgf receptor beta binding polypeptides |
PL2802606T3 (en) | 2012-01-10 | 2018-09-28 | Biogen Ma Inc. | Enhancement of transport of therapeutic molecules across the blood brain barrier |
EP3093293A1 (en) | 2012-02-24 | 2016-11-16 | Stemcentrx, Inc. | Anti dll3 antibodies and methods of use thereof |
AU2013203506B2 (en) | 2012-02-24 | 2016-06-09 | Abbvie Stemcentrx Llc | Novel modulators and methods of use |
CN117462693A (en) | 2012-02-27 | 2024-01-30 | 阿穆尼克斯运营公司 | XTEN conjugate compositions and methods of making the same |
CA2864177C (en) | 2012-03-01 | 2019-11-26 | Amgen Research (Munich) Gmbh | Prolonged half-life albumin-binding protein fused bispecific antibodies |
KR102367723B1 (en) | 2012-03-28 | 2022-02-28 | 사노피 | Antibodies to bradykinin b1 receptor ligands |
US9156915B2 (en) | 2012-04-26 | 2015-10-13 | Thomas Jefferson University | Anti-GCC antibody molecules |
MX2014013637A (en) | 2012-05-07 | 2015-02-05 | Sanofi Sa | Methods for preventing biofilm formation. |
JP2015518829A (en) | 2012-05-14 | 2015-07-06 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | LINGO-2 antagonist for treatment of conditions involving motor neurons |
WO2013175276A1 (en) | 2012-05-23 | 2013-11-28 | Argen-X B.V | Il-6 binding molecules |
WO2014028865A1 (en) | 2012-08-17 | 2014-02-20 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for detecting complement activation |
US10413620B2 (en) | 2012-08-17 | 2019-09-17 | The Regents Of The University Of Colorado, A Body Corporate | Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging |
PT2906235T (en) | 2012-10-02 | 2017-09-28 | Proclara Biosciences Inc | Use of p3 of bacteriophage fusion proteins as amyloid binding agents |
MX363407B (en) | 2012-12-10 | 2019-03-22 | Biogen Ma Inc | Anti-blood dendritic cell antigen 2 antibodies and uses thereof. |
US9771413B2 (en) | 2012-12-31 | 2017-09-26 | Neurimmune Holding Ag | Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases |
KR102204127B1 (en) | 2013-02-01 | 2021-01-20 | 키라 바이오테크 피티와이 리미티드 | Anti-cd83 antibodies and use thereof |
SG11201505762XA (en) | 2013-02-07 | 2015-08-28 | Csl Ltd | Il-11r binding proteins and uses thereof |
SI2958944T1 (en) | 2013-02-22 | 2019-08-30 | Abb Vie Stemcentrx Llc | Antidll3-antibody-pbd conjugates and uses thereof |
AR095374A1 (en) | 2013-03-15 | 2015-10-14 | Amgen Res (Munich) Gmbh | UNION MOLECULES FOR BCMA AND CD3 |
CA2902905A1 (en) | 2013-03-15 | 2014-09-25 | Claude Geoffrey Davis | Modified toxins |
MX2015011670A (en) | 2013-03-15 | 2016-03-31 | Biogen Ma Inc | Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies. |
AR095199A1 (en) | 2013-03-15 | 2015-09-30 | Genzyme Corp | ANTI-CD52 ANTIBODIES |
CA2907181C (en) | 2013-03-15 | 2023-10-17 | Viktor Roschke | Multivalent and monovalent multispecific complexes and their uses |
US9988444B2 (en) | 2013-05-28 | 2018-06-05 | Proclara Biosciences, Inc. | Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity |
JP6521959B2 (en) | 2013-07-31 | 2019-05-29 | ライナット ニューロサイエンス コーポレイション | Engineered polypeptide conjugates |
EP2832854A1 (en) | 2013-08-02 | 2015-02-04 | F. Hoffmann-La Roche AG | Method for improving the recombinant expression of a polypeptide by C-terminal fusion to human neprilysin |
TW201722994A (en) | 2013-08-13 | 2017-07-01 | 賽諾菲公司 | Antibodies to Plasminogen Activator Inhibitor-1 (PAI-1) and uses thereof |
PE20160244A1 (en) | 2013-08-13 | 2016-05-10 | Sanofi Sa | ANTIBODIES AGAINST PLASMINOGEN ACTIVATOR INHIBITOR TYPE 1 (PAI-1) AND USES OF THE SAME |
EP3892294A1 (en) | 2013-08-28 | 2021-10-13 | AbbVie Stemcentrx LLC | Site-specific antibody conjugation methods and compositions |
EP3338793A1 (en) | 2013-08-28 | 2018-06-27 | AbbVie Stemcentrx LLC | Novel sez6 modulators and methods of use |
CA2927695C (en) | 2013-10-21 | 2022-03-01 | Dyax Corp. | Diagnosis and treatment of autoimmune diseases |
ES2711882T3 (en) | 2013-11-28 | 2019-05-08 | B Creative Sweden Ab | Method of treatment of diabetic nephropathy |
WO2015089073A2 (en) | 2013-12-09 | 2015-06-18 | New York University | Compositions and methods for phagocyte delivery of anti-staphylococcal agents |
ES2851386T3 (en) | 2013-12-18 | 2021-09-06 | Csl Ltd | Wound treatment method |
KR20170008202A (en) | 2014-02-21 | 2017-01-23 | 애브비 스템센트알엑스 엘엘씨 | Anti-dll3 antibodies and drug conjugates for use in melanoma |
AU2015231155B2 (en) | 2014-03-21 | 2020-11-12 | X-Body, Inc. | Bi-specific antigen-binding polypeptides |
MX2016013970A (en) | 2014-04-25 | 2017-04-06 | Rinat Neuroscience Corp | Antibody-drug conjugates with high drug loading. |
EP3143137A4 (en) | 2014-05-14 | 2017-11-15 | Trustees of Dartmouth College | Deimmunized lysostaphin and methods of use |
JP6868394B2 (en) | 2014-05-16 | 2021-05-12 | ファイザー・インク | Bispecific antibody |
CN113332449B (en) | 2014-06-12 | 2023-12-22 | 石药集团巨石生物制药有限公司 | Enzymatic preparation of homogeneous antibody-drug conjugates |
WO2016016415A1 (en) | 2014-07-31 | 2016-02-04 | Amgen Research (Munich) Gmbh | Bispecific single chain antibody construct with enhanced tissue distribution |
TW201609812A (en) | 2014-07-31 | 2016-03-16 | 安美基研究(慕尼黑)公司 | Optimized cross-species specific bispecific single chain antibody constructs |
AR101669A1 (en) | 2014-07-31 | 2017-01-04 | Amgen Res (Munich) Gmbh | ANTIBODY CONSTRUCTS FOR CDH19 AND CD3 |
KR102051503B1 (en) | 2014-08-28 | 2019-12-03 | 화이자 인코포레이티드 | Stability-modulating linkers for use with antibody drug conjugates |
IL250902B (en) | 2014-09-16 | 2022-08-01 | Symphogen As | Anti-met antibodies and compositions |
AU2015326911B2 (en) | 2014-09-30 | 2021-07-08 | Neurimmune Holding Ag | Human-derived anti-dipeptide repeats (DPRs) antibody |
NZ731491A (en) | 2014-10-23 | 2021-12-24 | Kira Biotech Pty Ltd | Cd83 binding proteins and uses thereof |
US10584175B2 (en) | 2014-10-23 | 2020-03-10 | La Trobe University | FN14-binding proteins and uses thereof |
WO2016081835A2 (en) | 2014-11-21 | 2016-05-26 | University Of Maryland, Baltimore | Targeted structure-specific particulate delivery systems |
EP3227341A1 (en) | 2014-12-02 | 2017-10-11 | CeMM - Forschungszentrum für Molekulare Medizin GmbH | Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies |
CN107250154A (en) | 2014-12-03 | 2017-10-13 | 普罗克拉拉生物科学股份有限公司 | Include the polypeptide for the bacteriophage G3P amino acid sequences through modification for lacking Glycosylation signals |
US10940212B2 (en) | 2014-12-19 | 2021-03-09 | Monash University | IL-21 agonist antibodies and methods of treatment using same |
CA2973266A1 (en) | 2015-01-08 | 2016-07-14 | Biogen Ma Inc. | Lingo-1 antagonists and uses for treatment of demyelinating disorders |
MA43918A (en) | 2015-04-14 | 2018-12-05 | Chugai Pharmaceutical Co Ltd | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF ATOPIC DERMATITIS CONTAINING AN IL-31 ANTAGONIST AS ACTIVE SUBSTANCE |
MX2017013348A (en) | 2015-04-17 | 2018-08-01 | Amgen Res Munich Gmbh | Bispecific antibody constructs for cdh3 and cd3. |
TWI744242B (en) | 2015-07-31 | 2021-11-01 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for egfrviii and cd3 |
TW202346349A (en) | 2015-07-31 | 2023-12-01 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for dll3 and cd3 |
TWI829617B (en) | 2015-07-31 | 2024-01-21 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for flt3 and cd3 |
TWI717375B (en) | 2015-07-31 | 2021-02-01 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for cd70 and cd3 |
TWI796283B (en) | 2015-07-31 | 2023-03-21 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for msln and cd3 |
WO2017053290A1 (en) * | 2015-09-23 | 2017-03-30 | Research Corporation Technologies, Inc. | Ribotoxin molecules derived from sarcin and other related fungal ribotoxins |
BR112018011622A2 (en) | 2015-12-11 | 2018-11-27 | Dyax Corp | method to treat hereditary angioedema attack (hae) or reduce hae attack rate |
EA039859B1 (en) | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Bispecific antibody constructs binding egfrviii and cd3 |
CN114716557A (en) | 2016-02-03 | 2022-07-08 | 安进研发(慕尼黑)股份有限公司 | PSMA and CD3 bispecific T cell engaging antibody constructs |
MA43955B1 (en) | 2016-02-03 | 2022-02-28 | Amgen Inc | Bite-format bispecific anti-bcma and anti-cd3 antibodies |
JOP20170091B1 (en) | 2016-04-19 | 2021-08-17 | Amgen Res Munich Gmbh | Administration of a bispecific construct binding to CD33 and CD3 for use in a method for the treatment of myeloid leukemia |
MA45186A (en) * | 2016-06-03 | 2019-04-10 | Janssen Biotech Inc | AREAS OF TYPE III FIBRONECTIN BINDING TO SERIC ALBUMIN |
PE20190510A1 (en) | 2016-06-13 | 2019-04-10 | I Mab | ANTI-PD-L1 ANTIBODIES AND USES OF THE SAME |
JP2018035137A (en) | 2016-07-13 | 2018-03-08 | マブイミューン ダイアグノスティックス エイジーMabimmune Diagnostics Ag | Novel anti-fibroblast activated protein (FAP) binding agent and use thereof |
WO2018022479A1 (en) | 2016-07-25 | 2018-02-01 | Biogen Ma Inc. | Anti-hspa5 (grp78) antibodies and uses thereof |
US10647767B2 (en) | 2016-09-19 | 2020-05-12 | I-Mab Biopharma Co., Ltd. | Anti-GM-CSF antibodies and uses thereof |
CN110023339A (en) | 2016-09-23 | 2019-07-16 | Csl有限公司 | Coagulation factor binding protein and its application |
CA3045970A1 (en) | 2016-12-21 | 2018-06-28 | F. Hoffmann-La Roche Ag | Method for in vitro glycoengineering of antibodies |
AU2017381656B2 (en) | 2016-12-21 | 2020-07-02 | F. Hoffmann-La Roche Ag | Re-use of enzymes in in vitro glycoengineering of antibodies |
JP6850351B2 (en) | 2016-12-21 | 2021-03-31 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | In vitro sugar chain engineering of antibodies |
BR112019013238A2 (en) | 2017-01-20 | 2020-02-11 | Tayu Huaxia Biotech Medical Group Co., Ltd. | ANTI-PD-1 ANTIBODIES AND USES OF THE SAME |
AU2018213549B2 (en) | 2017-01-24 | 2022-02-03 | I-Mab Biopharma Co., Ltd. | Anti-CD73 antibodies and uses thereof |
JOP20190189A1 (en) | 2017-02-02 | 2019-08-01 | Amgen Res Munich Gmbh | Low ph pharmaceutical composition comprising t cell engaging antibody constructs |
CA3060856A1 (en) | 2017-05-05 | 2018-11-08 | Amgen Inc. | Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration |
CN110753703B (en) | 2017-05-23 | 2024-04-09 | 德国亥姆霍兹慕尼黑中心健康与环境研究中心(有限公司) | Novel CD73 antibodies, their preparation and use |
WO2019075519A1 (en) | 2017-10-18 | 2019-04-25 | Csl Limited | Human serum albumin variants and uses thereof |
WO2019089544A1 (en) | 2017-11-01 | 2019-05-09 | Tufts Medical Center, Inc. | Bispecific antibody constructs and methods of use |
BR112020010514A2 (en) | 2017-11-29 | 2020-11-24 | Csl Limited | method to treat or prevent ischemia-reperfusion injury |
BR112020011627A2 (en) | 2017-12-11 | 2020-11-17 | Amgen Inc. | continuous manufacturing process for bispecific antibody products |
WO2019126536A1 (en) | 2017-12-20 | 2019-06-27 | Alexion Pharmaceuticals Inc. | Humanized anti-cd200 antibodies and uses thereof |
UY38041A (en) | 2017-12-29 | 2019-06-28 | Amgen Inc | CONSTRUCTION OF BIESPECFIC ANTIBODY DIRECTED TO MUC17 AND CD3 |
WO2019145475A2 (en) | 2018-01-25 | 2019-08-01 | Acm Biolabs Pte Ltd | Polymersomes comprising a soluble encapsulated antigen as well as methods of making and uses thereof |
US20210048437A1 (en) | 2018-03-26 | 2021-02-18 | Glycanostiion , s.r.o. | Means and methods for glycoprofiling of a protein |
KR20200122409A (en) | 2018-05-10 | 2020-10-27 | 주식회사 뉴라클사이언스 | Anti-family with sequence similarity 19, member A5 antibody and methods of use thereof |
US20210238238A1 (en) | 2018-05-16 | 2021-08-05 | Csl Limited | Soluble complement receptor type i variants and uses thereof |
TW202021616A (en) | 2018-07-30 | 2020-06-16 | 美商安進公司 | Prolonged administration of a bispecific antibody construct binding to cd33 and cd3 |
MX2021001353A (en) | 2018-08-03 | 2021-04-13 | Amgen Res Munich Gmbh | Antibody constructs for cldn18.2 and cd3. |
WO2020038397A1 (en) | 2018-08-21 | 2020-02-27 | I-Mab | Anti-pd-l1/anti-lag3 bispecific antibodies and uses thereof |
MX2021002332A (en) | 2018-08-27 | 2021-08-11 | Affimed Gmbh | Cryopreserved nk cells preloaded with an antibody construct. |
WO2020053325A1 (en) | 2018-09-12 | 2020-03-19 | Acm Biolabs Pte Ltd | Polymersomes comprising a covalently bound antigen as well as methods of making and uses thereof |
US20210395298A1 (en) | 2018-10-11 | 2021-12-23 | Amgen Inc. | Downstream processing of bispecific antibody constructs |
US20220056136A1 (en) | 2018-11-30 | 2022-02-24 | Abl Bio Inc. | Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof |
WO2020118011A1 (en) | 2018-12-06 | 2020-06-11 | Alexion Pharmaceuticals, Inc. | Anti-alk2 antibodies and uses thereof |
CN113795513A (en) | 2019-02-13 | 2021-12-14 | 布里格姆妇女医院 | Anti-peripheral lymph node addressin antibody and use thereof |
EP3928790A4 (en) | 2019-02-22 | 2023-01-11 | Wuhan Yzy Biopharma Co., Ltd. | Cd3 antigen binding fragment and application thereof |
AU2020253455A1 (en) | 2019-04-03 | 2021-11-04 | Genzyme Corporation | Anti-alpha beta TCR binding polypeptides with reduced fragmentation |
MX2021014644A (en) | 2019-06-13 | 2022-04-06 | Amgen Inc | Automated biomass-based perfusion control in the manufacturing of biologics. |
US20220348650A1 (en) | 2019-09-03 | 2022-11-03 | Bio-Thera Solutions, Ltd. | Anti-tigit immunosuppressant and application thereof |
WO2021050640A1 (en) | 2019-09-10 | 2021-03-18 | Amgen Inc. | Purification method for bispecific antigen-binding polypeptides with enhanced protein l capture dynamic binding capacity |
US20220396599A1 (en) | 2019-11-13 | 2022-12-15 | Amgen Inc. | Method for Reduced Aggregate Formation in Downstream Processing of Bispecific Antigen-Binding Molecules |
TW202128222A (en) | 2019-11-20 | 2021-08-01 | 日商中外製藥股份有限公司 | Antibody-containing formulations |
CA3164129A1 (en) | 2019-12-20 | 2021-06-24 | Amgen Inc. | Mesothelin-targeted cd40 agonistic multispecific antibody constructs for the treatment of solid tumors |
EP4077385A4 (en) | 2019-12-20 | 2023-12-13 | Hudson Institute of Medical Research | Cxcl10 binding proteins and uses thereof |
CA3160927A1 (en) | 2019-12-27 | 2021-07-01 | Affimed Gmbh | Method for the production of bispecific fcyriii x cd30 antibody construct |
US20230093169A1 (en) | 2020-01-22 | 2023-03-23 | Amgen Research (Munch) Gmbh | Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof |
WO2021183861A1 (en) | 2020-03-12 | 2021-09-16 | Amgen Inc. | Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor |
WO2021188851A1 (en) | 2020-03-19 | 2021-09-23 | Amgen Inc. | Antibodies against mucin 17 and uses thereof |
EP4130035A1 (en) | 2020-03-31 | 2023-02-08 | Bio-Thera Solutions, Ltd. | Antibody and fusion protein for treating coronaviruses and use thereof |
EP3909601A1 (en) | 2020-05-11 | 2021-11-17 | LeukoCom GmbH | A novel antibody binding specifically to human ceacam1/3/5 and use thereof |
EP4153633A1 (en) | 2020-05-19 | 2023-03-29 | Amgen Inc. | Mageb2 binding constructs |
MX2022014902A (en) | 2020-05-29 | 2023-01-04 | Amgen Inc | Adverse effects-mitigating administration of a bispecific antibody construct binding to cd33 and cd3. |
WO2022013613A2 (en) | 2020-07-17 | 2022-01-20 | Onena Medicines S.L. | Antibodies against lefty proteins |
JP2023537022A (en) | 2020-08-07 | 2023-08-30 | バイオ-テラ ソリュ-ションズ,エルティーディー. | Anti-PD-L1 antibody and its application |
CA3187272A1 (en) | 2020-10-08 | 2022-04-14 | Thorsten Ross | Trispecific binders |
CN116323671A (en) | 2020-11-06 | 2023-06-23 | 安进公司 | Multi-targeting bispecific antigen binding molecules with increased selectivity |
BR112023008670A2 (en) | 2020-11-06 | 2024-02-06 | Amgen Inc | POLYPEPTIDE CONSTRUCTS LINKED TO CD3 |
BR112023008629A2 (en) | 2020-11-06 | 2023-10-03 | Amgen Inc | POLYPEPTIDE CONSTRUCTS THAT SELECTIVELY BIND CLDN6 AND CD3 |
TW202233678A (en) | 2020-11-06 | 2022-09-01 | 德商安美基研究(慕尼黑)公司 | Polypeptides with enhanced clipping profile |
JP2023551113A (en) | 2020-11-06 | 2023-12-07 | バイオ-テラ ソリュ-ションズ,エルティーディー. | Bispecific antibodies and their applications |
WO2022143794A1 (en) | 2020-12-30 | 2022-07-07 | 百奥泰生物制药股份有限公司 | Anti-cldn18.2 antibody, and preparation method therefor and use thereof |
CA3214934A1 (en) | 2021-04-12 | 2022-10-20 | Madhavan Nallani | Polymersomes comprising a soluble encapsulated polynucleotide and an ionizable lipid as well as methods of making and uses thereof |
CN117279947A (en) | 2021-05-06 | 2023-12-22 | 安进研发(慕尼黑)股份有限公司 | Antigen binding molecules targeting CD20 and CD22 for use in proliferative diseases |
CA3216098A1 (en) | 2021-07-30 | 2023-02-02 | Uwe Reusch | Duplexbodies |
WO2023051663A1 (en) | 2021-09-30 | 2023-04-06 | 百奥泰生物制药股份有限公司 | Anti-b7-h3 antibody and application thereof |
CA3237018A1 (en) | 2021-11-03 | 2023-05-11 | Joachim Koch | Bispecific cd16a binders |
AU2022382368A1 (en) | 2021-11-03 | 2024-05-02 | Affimed Gmbh | Bispecific cd16a binders |
WO2023180346A1 (en) | 2022-03-22 | 2023-09-28 | Morphosys Ag | Deimmunized antibodies specific for cd3 |
TW202346368A (en) | 2022-05-12 | 2023-12-01 | 德商安美基研究(慕尼黑)公司 | Multichain multitargeting bispecific antigen-binding molecules of increased selectivity |
WO2024059675A2 (en) | 2022-09-14 | 2024-03-21 | Amgen Inc. | Bispecific molecule stabilizing composition |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992010755A1 (en) * | 1990-12-05 | 1992-06-25 | Novo Nordisk A/S | Proteins with changed epitopes and methods for the production thereof |
EP0699755A2 (en) * | 1994-06-30 | 1996-03-06 | Centro de Inmunologia Molecular | Method for obtaining modified immunoglobulins with reduced immunogenicity of murine antibody variable domains, compositions containing them |
EP0721982A1 (en) * | 1995-01-06 | 1996-07-17 | Leuven Research & Development V.Z.W. | New staphylokinase derivatives |
WO1998052976A1 (en) * | 1997-05-21 | 1998-11-26 | Biovation Limited | Method for the production of non-immunogenic proteins |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR9607647A (en) * | 1995-03-17 | 1999-04-06 | Novo Nordisk As | Insulin derivative and pharmaceutical composition and process for the treatment of diabetes in a patient in need of this treatment |
-
1999
- 1999-12-08 EP EP99959535A patent/EP1051432B1/en not_active Expired - Lifetime
- 1999-12-08 AT AT99959535T patent/ATE352559T1/en not_active IP Right Cessation
- 1999-12-08 CN CNB998044016A patent/CN1202128C/en not_active Expired - Fee Related
- 1999-12-08 JP JP2000586759A patent/JP2002534959A/en active Pending
- 1999-12-08 DE DE69934967T patent/DE69934967T2/en not_active Expired - Fee Related
- 1999-12-08 WO PCT/GB1999/004119 patent/WO2000034317A2/en active IP Right Grant
- 1999-12-08 CA CA002342967A patent/CA2342967A1/en not_active Abandoned
- 1999-12-08 ES ES99959535T patent/ES2278463T3/en not_active Expired - Lifetime
- 1999-12-08 AU AU16676/00A patent/AU776910B2/en not_active Ceased
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992010755A1 (en) * | 1990-12-05 | 1992-06-25 | Novo Nordisk A/S | Proteins with changed epitopes and methods for the production thereof |
EP0699755A2 (en) * | 1994-06-30 | 1996-03-06 | Centro de Inmunologia Molecular | Method for obtaining modified immunoglobulins with reduced immunogenicity of murine antibody variable domains, compositions containing them |
EP0721982A1 (en) * | 1995-01-06 | 1996-07-17 | Leuven Research & Development V.Z.W. | New staphylokinase derivatives |
WO1998052976A1 (en) * | 1997-05-21 | 1998-11-26 | Biovation Limited | Method for the production of non-immunogenic proteins |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8835606B2 (en) | 2004-01-22 | 2014-09-16 | Merck Patent Gmbh | Anti-cancer antibodies with reduced complement fixation |
US9221915B2 (en) | 2005-09-07 | 2015-12-29 | Pfizer Inc. | Human monoclonal antibodies to activin receptor-like kinase-1 |
US8691952B2 (en) | 2005-12-30 | 2014-04-08 | Merck Patent Gmbh | Anti-CD19 antibodies with reduced immunogenicity |
US8957195B2 (en) | 2005-12-30 | 2015-02-17 | Merck Patent Gmbh | Anti-CD19 antibodies with reduced immunogenicity |
US9096651B2 (en) | 2007-09-26 | 2015-08-04 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in CDR |
US9399680B2 (en) | 2007-12-05 | 2016-07-26 | Chugai Seiyaku Kabushiki Kaisha | Nucleic acids encoding anti-NR10 antibodies |
US9228017B2 (en) | 2009-03-19 | 2016-01-05 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
US9066925B2 (en) | 2009-07-02 | 2015-06-30 | Musc Foundation For Research Development | Methods of stimulating liver regeneration |
US8524470B2 (en) | 2009-07-30 | 2013-09-03 | Hoffman-La Roche, Inc. | Enzymatic antibody processing |
US9011852B2 (en) | 2010-04-30 | 2015-04-21 | Alexion Pharmaceuticals, Inc. | Anti-C5a antibodies |
US9133273B2 (en) | 2010-11-19 | 2015-09-15 | Eisai R&D Management Co., Ltd. | Nucleic acids encoding neutralizing anti-CCL20 antibodies |
Also Published As
Publication number | Publication date |
---|---|
AU776910B2 (en) | 2004-09-23 |
CN1202128C (en) | 2005-05-18 |
ATE352559T1 (en) | 2007-02-15 |
DE69934967T2 (en) | 2007-12-06 |
CA2342967A1 (en) | 2000-06-15 |
EP1051432B1 (en) | 2007-01-24 |
DE69934967D1 (en) | 2007-03-15 |
CN1294596A (en) | 2001-05-09 |
ES2278463T3 (en) | 2007-08-01 |
AU1667600A (en) | 2000-06-26 |
EP1051432A2 (en) | 2000-11-15 |
WO2000034317A2 (en) | 2000-06-15 |
JP2002534959A (en) | 2002-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000034317A3 (en) | Method for reducing immunogenicity of proteins | |
CA2290485A1 (en) | Method for the production of non-immunogenic proteins | |
EP2311952A3 (en) | Antibodies to MRT-1 protein or fragments thereof | |
CA2102208A1 (en) | Binding domains in notch and delta proteins | |
EP0909814A3 (en) | Use of protein kinases for the diagnosis and treatment of Alzheimer's disease | |
WO1996028470A3 (en) | Peptide analogues of human myelin basic protein useful in treating multiple sclerosis | |
WO1994021675A3 (en) | T cell epitopes of ryegrass pollen allergen | |
WO1993021321A3 (en) | T CELL EPITOPES OF THE MAJOR ALLERGENS FROM $i(AMBROSIA ARTEMISIIFOLIA) | |
HUP0100267A2 (en) | Nucleic acid and amino acid sequences relating to helicobacter pylori and vaccine compositions thereof | |
EP0716591A4 (en) | METHODS AND COMPOSITIONS FOR BINDING TAU AND MAP2c PROTEINS | |
NZ335633A (en) | Production of recombinant H. pylori polypeptides for treatment and diagnosis of H. pylori related diseases | |
WO2002006302A3 (en) | 16816 and 16839, novel human phospholipase c molecules and uses therefor | |
EP1233024A3 (en) | 25466, a human transporter family member and uses therefor | |
WO2003018829A3 (en) | 6299, a human zinc carboxypeptidase family member and uses therefor | |
WO2001075121A3 (en) | 16836, a human phospholipase c family member and uses thereof | |
WO2001094412A3 (en) | 56201, a novel human sodium ion channel family member and uses thereof | |
WO2001094563A3 (en) | 46980, a novel human neuroligin family member and uses thereof | |
WO2001066764A3 (en) | 16835, a human phospholipase c and uses thereof | |
TR200002611T2 (en) | Beta-lipotropin and its uses | |
WO2001090146A3 (en) | 57256 and 58289, human transporters and uses thereof | |
EP1225182A3 (en) | Human phospholipid transporter | |
WO2002018439A3 (en) | 52991, a human transporter protein and uses therefor | |
WO2002008395A3 (en) | Putative human methyltransferase family member and uses thereof | |
WO2001096375A3 (en) | 33358, a novel human ankyrin family member and uses thereof | |
WO2002038773A3 (en) | A human phospholipase c and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 99804401.6 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2000 16676 Country of ref document: AU Kind code of ref document: A |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09633516 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2000/007746 Country of ref document: MX |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999959535 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 16676/00 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 1999959535 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2342967 Country of ref document: CA Ref document number: 2342967 Country of ref document: CA Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 16676/00 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1999959535 Country of ref document: EP |